Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Inclusion Criteria

• •Newly diagnosed MGMT unmethylated glioblastoma multiforme (no prior treatment)
• •Sufficient cancer tissue obtained to allow for manufacture of autologous cancer cell vaccines
• •The attenuated autologous cancer cell product generated has satisfied the product release criteria as determined by the sponsor quality control department
• •Medical history, physical examination and laboratory testing performed within approximately 7 days before enrollment revealing kidney and liver organ function within normal limits
• •not currently receiving glucocorticoids and have been off glucocorticoids for at least 24 hours prior to vaccination as well as when they receive the T cell infusion.
• •Patient function assessment (Karnofsky score is \> 60)
• •a life expectancy of \> 12 weeks.
• •Hemoglobin is \> 10 g/dL (may be transfused)
• •White blood cell count is \> 3,000 cells/microliter (mcL) of blood.
• •Platelet count is \> 100,000 platelets per mcL of blood (transfusion independent)
• •Lymphocyte count is \> 1,000 cells/mcL of blood.